Shots:

• Lupin to receive $30M upfront- up to $947M milestones and royalties on sales. AbbVie to get exclusive worldwide (Ex. India) rights to develop and commercialize Lupin’s MALT1 inhibitors
• The focus of the agreement is to utilize Lupin’s Drug Discovery platform to develop treatments for multiple hematological cancers
• MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) Inhibitor Program involves protein MALT-1- targeted for the activation of T-cell and B-cell lymphocytes

Ref: Lupin | Image: AbbVie